A monoclonal antibody is secreted by a single B lymphocyte clone which can only produce a kind of proprietary antibody against an antigen-determining cluster, and has the characteristics of single biological activity and particular specificity of binding with antigen.
The active sites of monoclonal antibody drugs involve a variety of tumor-related signaling pathways and targets. For example, the most common targets are epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), and epidermal growth factor receptor -2 (her-2 /neu, or egfr-2). Besides, there is a group of targets that are getting a lot of attention called “immune checkpoints”.
After the activation of immune cells that regulate the anti-tumor immune response, a variety of highly expressed receptors on the surface of immune cells bind to the highly expressed ligands on the surface of tumor cells to reduce the strength of the immune response, thus down-regulating the intensity of tumor-related immune response. These immunoregulatory sites are known as immune checkpoints. Currently, the most widely studied immune checkpoints are PD-1, PD-L1, and CTLA-4.
Targetmol provides xnum monoclonal antibody drugs, including the above immune checkpoint inhibitors and other types of targeted antibody inhibitors, for scientific research only.
Cat. No. | Product name | CAS No. | Purity | Chemical Structure |
---|---|---|---|---|
T9901A-005 | Zolbetuximab | 1496553-00-4 | 98% |
|
Zolbetuximab(IMAB362) is a monoclonal antibody that specifically targets Claudin-18.2.Zolbetuximab has potential antitumor activity, mediating killing of Claudin... | ||||
T9901A-007 | Datopotamab | 2267989-53-5 | 98% |
Datopotamab
|
Datopotamab (CDP7657) is a TROP2-targeting antibody that is a naked antibody to Datopotamab deruxtecan and can be used to synthesize active antibody conjugators ... | ||||
T77747 | Adecatumumab | 503605-66-1 | 98% |
Adecatumumab
|
Adecatumumab (MT201) is a whole-person IgG1 monoclonal antibody to human EpCAM. Adecatumumab has potential anticancer activity and can be used to study breast ca... | ||||
T77748 | Tusamitamab | 2349294-95-5 | 98% |
|
Tusamitamab is an IgG1 monoclonal antibody targeting CEACAM5 and is the naked antibody to Tusamitamab ravtansine.Tusamitamab can be used to synthesize the antibo... | ||||
T77749 | Upifitamab | 2254118-43-7 | 98% |
Upifitamab
|
Upifitamab is a naked antibody to upifitamab rilsodotin, which can be used to synthesize the antibody-coupled active molecule UPRI, which can be used to study ca... | ||||
T77750 | Rosmantuzumab | 1684393-04-1 | 98% |
Rosmantuzumab
|
Rosmantuzumab (OMP-131R10) is a humanized monoclonal antibody against R-spondin 3 (RSPO3). Rosmantuzumab has potential antitumor activity and can be used to stud... | ||||
T77751 | Imaprelimab | 2014343-04-3 | 98% |
Imaprelimab
|
Imaprelimab (PRX-003) is a humanized IgG1 κmonoclonal antibody against melanoma cell adhesion molecule (MCAM). Imaprelimab has antitumor activity and can be used... | ||||
T78268 | Anti-Mouse NK1.1 Antibody (PK136) | 98% |
Anti-Mouse NK1.1 Antibody (PK136)
|
|
Anti-Mouse NK1.1 Antibody (PK136) is an IgG2a class antibody of murine origin targeting NK1.1, which eliminates NK1.1 and NK1.1NKT cells and inhibits NK1.1 signa... | ||||
T78337 | Mouse IgG2a kappa, Isotype Control | 98% |
Mouse IgG2a kappa, Isotype Control
|
|
Mouse IgG2a kappa, Isotype Control is an isotype antibody to murine-derived IIgG2a kappa antibody. | ||||
T9916 | Alirocumab | 1245916-14-6 | 98% |
Alirocumab
|
Alirocumab is a human monoclonal antibody that inhibits PCSK9. It is produced by recombinant DNA technology in Chinese hamster ovary cell suspension culture. | ||||
T9912 | Trastuzumab | 180288-69-1 | 98% |
|
Trastuzumab is a humanized monoclonal antibody for patients with invasive breast cancers that overexpress HER2. Trastuzumab has been clinically used to treat HER... | ||||
T9908 | Pembrolizumab | 1374853-91-4 | 98% |
Pembrolizumab
|
Pembrolizumab is a humanized monoclonal antibody inhibiting the PD-1 receptor and the first in the class of agents called the HER2 dimerization inhibitors that i... | ||||
T9919 | Alemtuzumab | 216503-57-0 | 98% |
Alemtuzumab
|
Alemtuzumab is a humanized monoclonal antibody against CD52 an antigen found on the surface of normal and malignant lymphocytes. | ||||
T38362 | Guselkumab | 1350289-85-8 | 98% |
|
Guselkumab (CNTO 1959) is a recombinant human IgG1 monoclonal antibody targeting the IL-23p19 subunit. Guselkumab binds to human cynomolgus monkey IL-23 with Kd ... | ||||
T9918 | Daratumumab | 945721-28-8 | 98% |
|
Daratumumab is a human monoclonal antibody that targets CD38 a cell surface protein that is overexpressed on multiple myeloma MM) cells. | ||||
T35394 | Sintilimab (anti-PD-1) | 2072873-06-2 | 98% |
Sintilimab (anti-PD-1)
|
Sintilimab (IBI308) is a humanized IgG4 monoclonal antibody with significant anti-tumor activity that restores endogenous anti-tumor T-cell responses by binding ... | ||||
T9914 | Vedolizumab | 943609-66-3 | 98% |
|
Vedolizumab is a humanized monoclonal antibody that targets the α4β7 integrin for the treatment of Crohn's disease and ulcerative colitis. | ||||
T73689 | Daclizumab | 152923-56-3 | 98% |
Daclizumab
|
Daclizumab (Zenapax) is a humanized monoclonal antibody that specifically inhibits the alpha subunit of IL-2R-HA. Daclizumab (Zenapax) can inhibit the binding of... | ||||
T73695 | Canakinumab | 914613-48-2 | 98% |
|
Canakinumab (ACZ885) is a recombinant human IL-1β-targeting monoclonal antibody.Canakinumab has been shown to inhibit human and chorioallantoic monkey IL-1β, wit... | ||||
T73698 | Basiliximab | 179045-86-4 | 98% |
Basiliximab
|
Basiliximab (CHI 621) is a chimeric mouse/human IgG1 monoclonal recombinant antibody against the interleukin-2 receptor. Basiliximab has good immunosuppressive a... |